{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:13:05Z","timestamp":1792188785090,"version":"4.4.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40257-021-00594-8","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T07:02:59Z","timestamp":1618815779000},"page":"315-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["50 Years of Topical Retinoids for Acne: Evolution of Treatment"],"prefix":"10.1007","volume":"22","author":[{"given":"Hilary","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Callender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran E.","family":"Cook-Bolden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"594_CR1","unstructured":"US Food and Drug Administration. Drugs@FDA-Approved Drugs. 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=016921. Accessed 28 Apr 2020."},{"issue":"3","key":"594_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s13555-017-0185-2","volume":"7","author":"J Leyden","year":"2017","unstructured":"Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293\u2013304.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"Suppl 1","key":"594_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","volume":"26","author":"A Nast","year":"2012","unstructured":"Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1\u201329.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"5 Suppl","key":"594_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2009.01.019","volume":"60","author":"D Thiboutot","year":"2009","unstructured":"Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1\u201350.","journal-title":"J Am Acad Dermatol."},{"key":"594_CR5","doi-asserted-by":"crossref","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u201373 e33.","DOI":"10.1016\/j.jaad.2015.12.037"},{"issue":"6 Pt 2","key":"594_CR6","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/S0190-9622(97)70049-5","volume":"36","author":"AM Kligman","year":"1997","unstructured":"Kligman AM. The treatment of acne with topical retinoids: one man\u2019s opinions. J Am Acad Dermatol. 1997;36(6 Pt 2):S92\u20135.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"594_CR7","first-page":"255","volume":"18","author":"J Tan","year":"2019","unstructured":"Tan J, Tanghetti E, Baldwin H, Stein Gold L, Lain E. The role of topical retinoids in prevention and treatment of atrophic acne scarring: understanding the importance of early effective treatment. J Drugs Dermatol. 2019;18(3):255\u201360.","journal-title":"J Drugs Dermatol."},{"issue":"7","key":"594_CR8","first-page":"20","volume":"3","author":"EC Davis","year":"2010","unstructured":"Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20\u201331.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"3","key":"594_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40257-016-0185-5","volume":"17","author":"RR Riahi","year":"2016","unstructured":"Riahi RR, Bush AE, Cohen PR. Topical retinoids: therapeutic mechanisms in the treatment of photodamaged skin. Am J Clin Dermatol. 2016;17(3):265\u201376.","journal-title":"Am J Clin Dermatol."},{"issue":"3","key":"594_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13555-017-0194-1","volume":"7","author":"OA Ogbechie-Godec","year":"2017","unstructured":"Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatol Ther (Heidelb). 2017;7(3):305\u201318.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"594_CR11","doi-asserted-by":"publisher","first-page":"15029","DOI":"10.1038\/nrdp.2015.29","volume":"1","author":"S Moradi Tuchayi","year":"2015","unstructured":"Moradi Tuchayi S, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris. Nat Rev Dis Primers. 2015;1:15029.","journal-title":"Nat Rev Dis Primers."},{"issue":"2","key":"594_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.asj.2006.02.003","volume":"26","author":"CB Boswell","year":"2006","unstructured":"Boswell CB. Skincare science: update on topical retinoids. Aesthet Surg J. 2006;26(2):233\u20139.","journal-title":"Aesthet Surg J."},{"issue":"2","key":"594_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.clinthera.2005.02.009","volume":"27","author":"JJ Leyden","year":"2005","unstructured":"Leyden JJ, Shalita A, Thiboutot D, Washenik K, Webster G. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther. 2005;27(2):216\u201324.","journal-title":"Clin Ther."},{"issue":"4","key":"594_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1124\/pr.58.4.4","volume":"58","author":"P Germain","year":"2006","unstructured":"Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International union of pharmacology. LX. Retinoic acid receptors. Pharmacol Rev. 2006;58(4):712\u201325.","journal-title":"Pharmacol Rev."},{"issue":"4","key":"594_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/1523-1747.ep12469889","volume":"96","author":"JT Elder","year":"1991","unstructured":"Elder JT, Fisher GJ, Zhang QY, Eisen D, Krust A, Kastner P, et al. Retinoic acid receptor gene expression in human skin. J Invest Dermatol. 1991;96(4):425\u201333.","journal-title":"J Invest Dermatol."},{"issue":"9","key":"594_CR16","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1096\/fasebj.10.9.8801161","volume":"10","author":"GJ Fisher","year":"1996","unstructured":"Fisher GJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. FASEB J. 1996;10(9):1002\u201313.","journal-title":"FASEB J."},{"issue":"8","key":"594_CR17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","volume":"28","author":"S Khalil","year":"2017","unstructured":"Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat. 2017;28(8):684\u201396.","journal-title":"J Dermatolog Treat."},{"issue":"2 Pt 3","key":"594_CR18","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0190-9622(98)70440-2","volume":"39","author":"B Shroot","year":"1998","unstructured":"Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol. 1998;39(2 Pt 3):S17\u201324.","journal-title":"J Am Acad Dermatol."},{"issue":"Suppl 4","key":"594_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.13190","volume":"29","author":"B Dreno","year":"2015","unstructured":"Dreno B, Gollnick HP, Kang S, Thiboutot D, Bettoli V, Torres V, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015;29(Suppl 4):3\u201311.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"4","key":"594_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/archderm.1969.01610220097017","volume":"99","author":"AM Kligman","year":"1969","unstructured":"Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99(4):469\u201376.","journal-title":"Arch Dermatol."},{"issue":"3","key":"594_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/sder.2001.27555","volume":"20","author":"S Bershad","year":"2001","unstructured":"Bershad S. Developments in topical retinoid therapy for acne. Semin Cutan Med Surg. 2001;20(3):154\u201361.","journal-title":"Semin Cutan Med Surg."},{"issue":"5","key":"594_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.clindermatol.2004.03.013","volume":"22","author":"D Rigopoulos","year":"2004","unstructured":"Rigopoulos D, Ioannides D, Kalogeromitros D, Katsambas AD. Comparison of topical retinoids in the treatment of acne. Clin Dermatol. 2004;22(5):408\u201311.","journal-title":"Clin Dermatol."},{"issue":"5","key":"594_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/1523-1747.ep12606988","volume":"104","author":"S Chen","year":"1995","unstructured":"Chen S, Ostrowski J, Whiting G, Roalsvig T, Hammer L, Currier SJ, et al. Retinoic acid receptor gamma mediates topical retinoid efficacy and irritation in animal models. J Invest Dermatol. 1995;104(5):779\u201383.","journal-title":"J Invest Dermatol."},{"issue":"4 Pt 2","key":"594_CR24","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/S0190-9622(98)70308-1","volume":"39","author":"RA Chandraratna","year":"1998","unstructured":"Chandraratna RA. Rational design of receptor-selective retinoids. J Am Acad Dermatol. 1998;39(4 Pt 2):S124\u20138.","journal-title":"J Am Acad Dermatol."},{"issue":"2 Pt 1","key":"594_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0190-9622(87)70037-1","volume":"16","author":"CN Ellis","year":"1987","unstructured":"Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol. 1987;16(2 Pt 1):267\u201391.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"594_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/ijd.12365","volume":"53","author":"S Dogra","year":"2014","unstructured":"Dogra S, Yadav S. Acitretin in psoriasis: an evolving scenario. Int J Dermatol. 2014;53(5):525\u201338.","journal-title":"Int J Dermatol."},{"key":"594_CR27","unstructured":"US Food and Drug Administration. NDA-20-338. 1996. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/pre96\/020338Orig1s000rev.pdf. Accessed 29 Apr 2020."},{"issue":"6 Pt 2","key":"594_CR28","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/S0190-9622(97)70050-1","volume":"36","author":"B Shroot","year":"1997","unstructured":"Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997;36(6 Pt 2):S96\u2013103.","journal-title":"J Am Acad Dermatol."},{"issue":"6 Pt 2","key":"594_CR29","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/S0190-9622(97)70055-0","volume":"36","author":"J Allec","year":"1997","unstructured":"Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol. 1997;36(6 Pt 2):S119\u201325.","journal-title":"J Am Acad Dermatol."},{"issue":"3 Pt 2","key":"594_CR30","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0190-9622(97)70059-8","volume":"36","author":"L Latriano","year":"1997","unstructured":"Latriano L, Tzimas G, Wong F, Wills RJ. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol. 1997;36(3 Pt 2):S37-46.","journal-title":"J Am Acad Dermatol."},{"issue":"Suppl 1","key":"594_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000051370","volume":"199","author":"JH Saurat","year":"1999","unstructured":"Saurat JH, Sorg O. Topical natural retinoids. The \u201cproligand-non-ligand\u201d concept. Dermatology. 1999;199(Suppl 1):1\u20132.","journal-title":"Dermatology"},{"key":"594_CR32","doi-asserted-by":"crossref","unstructured":"Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139(Suppl 52):48\u201356.","DOI":"10.1046\/j.1365-2133.1998.1390s2048.x"},{"key":"594_CR33","unstructured":"Tazorac\u00ae[package insert]. Irvine: Allergan, Inc.; 1997."},{"issue":"6","key":"594_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S0190-9622(99)70248-3","volume":"41","author":"D Hecker","year":"1999","unstructured":"Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol. 1999;41(6):927\u201330.","journal-title":"J Am Acad Dermatol."},{"key":"594_CR35","unstructured":"Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(6 Suppl):4\u20139."},{"key":"594_CR36","unstructured":"Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(2 Suppl):4\u201311."},{"issue":"2","key":"594_CR37","first-page":"153","volume":"4","author":"A Shalita","year":"2005","unstructured":"Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol. 2005;4(2):153\u20138.","journal-title":"J Drugs Dermatol."},{"issue":"3","key":"594_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-019-00423-z","volume":"20","author":"SS Kolli","year":"2019","unstructured":"Kolli SS, Pecone D, Pona A, Cline A, Feldman SR. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20(3):345\u201365.","journal-title":"Am J Clin Dermatol."},{"key":"594_CR39","unstructured":"Tolaymat L, Zito PM. Adapalene. [Updated 2020 Sep 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021-Jan. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482509\/"},{"key":"594_CR40","doi-asserted-by":"crossref","unstructured":"Latter G, Grice JE, Mohammed Y, Roberts MS, Benson HAE. Targeted topical delivery of retinoids in the management of acne vulgaris: current formulations and novel delivery systems. Pharmaceutics. 2019;11(10):490.","DOI":"10.3390\/pharmaceutics11100490"},{"issue":"13","key":"594_CR41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2019.22507","volume":"323","author":"The medical letter on drugs and therapeutics","year":"2020","unstructured":"The medical letter on drugs and therapeutics. Trifarotene (Aklief\u00ae)\u2014A new topical retinoid for acne. JAMA. 2020;323(13):1310\u20131.","journal-title":"JAMA"},{"issue":"6","key":"594_CR42","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","volume":"80","author":"J Tan","year":"2019","unstructured":"Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, et al. Randomized phase 3 evaluation of trifarotene 50 \u03bcg\/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"594_CR43","unstructured":"Aklief\u00ae [package insert]. Galderma Laboratories L, Switzerland; 2019."},{"issue":"6","key":"594_CR44","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/1203475415591117","volume":"19","author":"L Culp","year":"2015","unstructured":"Culp L, Moradi Tuchayi S, Alinia H, Feldman SR. Tolerability of topical retinoids: are there clinically meaningful differences among topical retinoids? J Cutan Med Surg. 2015;19(6):530\u20138.","journal-title":"J Cutan Med Surg."},{"key":"594_CR45","unstructured":"Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol. 2008;18(5):524\u20136."},{"key":"594_CR46","unstructured":"Feldman SR, Werner CP, Alio Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013;12(4):438\u201346."},{"issue":"6","key":"594_CR47","first-page":"641","volume":"3","author":"J Leyden","year":"2004","unstructured":"Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3(6):641\u201351.","journal-title":"J Drugs Dermatol."},{"issue":"6","key":"594_CR48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2165\/0128071-200809060-00003","volume":"9","author":"A Thielitz","year":"2008","unstructured":"Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369\u201381.","journal-title":"Am J Clin Dermatol."},{"key":"594_CR49","doi-asserted-by":"crossref","unstructured":"Pomerantz H, Weinstock MA, VATTC. Predictors of local adverse effects caused by topical tretinoin cream 0.1% in the Veterans Affairs Topical Tretinoin Chemoprevention trial. Br J Dermatol. 2014;171(3):642\u20135.","DOI":"10.1111\/bjd.12987"},{"issue":"4","key":"594_CR50","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-4632.2010.04416.x","volume":"49","author":"B Dreno","year":"2010","unstructured":"Dreno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448\u201356.","journal-title":"Int J Dermatol."},{"issue":"2","key":"594_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaad.2006.05.073","volume":"56","author":"J Krejci-Manwaring","year":"2007","unstructured":"Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56(2):211\u20136.","journal-title":"J Am Acad Dermatol."},{"issue":"8 Suppl 3","key":"594_CR52","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","volume":"51","author":"MA Raebel","year":"2013","unstructured":"Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11\u201321.","journal-title":"Med Care."},{"issue":"6","key":"594_CR53","first-page":"S6","volume":"17","author":"LK Hoffman","year":"2018","unstructured":"Hoffman LK, Bhatia N, Zeichner J, Kircik LH. Topical vehicle formulations in the treatment of acne. J Drugs Dermatol. 2018;17(6):S6\u201310.","journal-title":"J Drugs Dermatol."},{"issue":"2s","key":"594_CR54","first-page":"S100","volume":"18","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Kircik LH, Zeichner J, Stein GL. The clinical relevance and therapeutic benefit of established active ingredients incorporated into advanced foam vehicles: vehicle characteristics can influence and improve patient outcomes. J Drugs Dermatol. 2019;18(2s):S100\u20137.","journal-title":"J Drugs Dermatol."},{"issue":"6","key":"594_CR55","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jamadermatol.2014.5254","volume":"151","author":"KL Anderson","year":"2015","unstructured":"Anderson KL, Dothard EH, Huang KE, Feldman SR. Frequency of primary nonadherence to acne treatment. JAMA Dermatol. 2015;151(6):623\u20136.","journal-title":"JAMA Dermatol."},{"issue":"3","key":"594_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40257-013-0016-x","volume":"14","author":"X Tan","year":"2013","unstructured":"Tan X, Al-Dabagh A, Davis SA, Lin HC, Balkrishnan R, Chang J, et al. Medication adherence, healthcare costs and utilization associated with acne drugs in Medicaid enrollees with acne vulgaris. Am J Clin Dermatol. 2013;14(3):243\u201351.","journal-title":"Am J Clin Dermatol."},{"issue":"1","key":"594_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","volume":"10","author":"AM Peterson","year":"2007","unstructured":"Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3\u201312.","journal-title":"Value Health."},{"key":"594_CR58","doi-asserted-by":"crossref","unstructured":"Dikicier BS. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. J Int Med Res. 2019;47(7):2987\u201392.","DOI":"10.1177\/0300060519847367"},{"issue":"5","key":"594_CR59","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3109\/09546634.2012.751085","volume":"24","author":"S Veraldi","year":"2013","unstructured":"Veraldi S, Barbareschi M, Benardon S, Schianchi R. Short contact therapy of acne with tretinoin. J Dermatolog Treat. 2013;24(5):374\u20136.","journal-title":"J Dermatolog Treat."},{"key":"594_CR60","unstructured":"Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis. 2001;67(6 Suppl):10\u201316."},{"issue":"2 Pt 3","key":"594_CR61","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S0190-9622(98)70448-7","volume":"39","author":"D Piacquadio","year":"1998","unstructured":"Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39(2 Pt 3):S67\u201373.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"594_CR62","first-page":"s148","volume":"18","author":"LH Kircik","year":"2019","unstructured":"Kircik LH, Draelos ZD, Berson DS. Polymeric emulsion technology applied to tretinoin. J Drugs Dermatol. 2019;18(4):S148\u201354.","journal-title":"J Drugs Dermatol."},{"issue":"3","key":"594_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4103\/0110-5558.72416","volume":"1","author":"S Kaity","year":"2010","unstructured":"Kaity S, Maiti S, Ghosh AK, Pal D, Ghosh A, Banerjee S. Microsponges: a novel strategy for drug delivery system. J Adv Pharm Technol Res. 2010;1(3):283\u201390.","journal-title":"J Adv Pharm Technol Res."},{"issue":"5","key":"594_CR64","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3109\/02652049609026042","volume":"13","author":"K Embil","year":"1996","unstructured":"Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13(5):575\u201388.","journal-title":"J Microencapsul."},{"issue":"8 Suppl","key":"594_CR65","first-page":"S2","volume":"7","author":"M Nighland","year":"2008","unstructured":"Nighland M, Grossman R. Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis. J Drugs Dermatol. 2008;7(8 Suppl):S2\u20138.","journal-title":"J Drugs Dermatol."},{"issue":"11","key":"594_CR66","first-page":"1268","volume":"12","author":"LH Kircik","year":"2013","unstructured":"Kircik LH. The microsponge delivery system reduces facial oiliness and shine during acne therapy. J Drugs Dermatol. 2013;12(11):1268\u201370.","journal-title":"J Drugs Dermatol."},{"key":"594_CR67","doi-asserted-by":"crossref","unstructured":"Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol. 1998;38(4):S17\u201323.","DOI":"10.1016\/S0190-9622(98)70141-0"},{"key":"594_CR68","unstructured":"Torok HM, Pillai R. Safety and efficacy of micronized tretinoin gel (0.05%) in treating adolescent acne. J Drugs Dermatol. 2011;10(6):647\u201352."},{"key":"594_CR69","unstructured":"Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084\u201391."},{"key":"594_CR70","doi-asserted-by":"crossref","unstructured":"Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R. Optimized formulation for topical application of a fixed combination halobetasol\/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2019:1\u20138.","DOI":"10.25251\/skin.3.supp.27"},{"key":"594_CR71","doi-asserted-by":"crossref","unstructured":"Tanghetti EA, Kircik LH, Green LJ, Guenin E, Harris S, Martin G, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542.","DOI":"10.36849\/JDD.2020.3977"},{"key":"594_CR72","doi-asserted-by":"crossref","unstructured":"Tanghetti EA, Werschler WP, Lain T, Guenin E, Martin G, Pillai R. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70\u20137.","DOI":"10.36849\/JDD.2020.3977"},{"key":"594_CR73","unstructured":"Data on file, Bausch Health Americas, Inc. Studies V01-121A-301 and V01-121A-302."},{"key":"594_CR74","unstructured":"Data on file, Bausch Health Americas, Inc. Studies V01-123A-301 and V01-123A-302."},{"key":"594_CR75","unstructured":"Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J et al. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2010;9(6):639\u201346."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00594-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00594-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00594-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T21:04:40Z","timestamp":1675199080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00594-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00594-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"19 April 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing support for this review article was funded by Ortho Dermatologics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hilary Baldwin has served as advisor, investigator, and on speakers\u2019 bureaus for Almirall, Cassiopea, Foamix, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharmaceuticals. Guy Webster has served as a consultant, speaker, or investigator for Ortho Dermatologics, Galderma, Almirall, Foamix Pharmaceuticals, and Sol-Gel Technologies. Linda Stein Gold has served as investigator, consultant, or speaker for Ortho Dermatologics, LEO Pharma, Dermavant, Incyte, Novartis, AbbVie, Pfizer, Sun Pharmaceuticals, UCB, Arcutis, and Lilly. Valerie Callender has served as an investigator, consultant, or speaker for Allergan, Galderma, L\u2019Or\u00e9al, and Ortho Dermatologics. Fran E. Cook-Bolden has served as consultant, speaker, or investigator for Galderma, LEO Pharma, Almirall, Cassiopea, Ortho Dermatologics, Investigators Encore, Foamix Pharmaceuticals, Hovione, Aclaris, and Cutanea. Eric Guenin is an employee of Ortho Dermatologics and may hold stock and\/or stock options in its parent company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"All authors made substantial contributions to the conception or design of the work; drafted the work\/revised it critically; approved the version to be published; and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}